Table 9. Correlations between CTC and molecular expression in lung large cell carcinoma.
| Molecular expression | Negative, N (%) | Positive, N (%) | Unknown, N (%) | Correlation coefficient | P |
|---|---|---|---|---|---|
| TTF-1 (10%) | 33 (33.33) | 42 (42.42) | 24 (24.24) | −0.357 | 0.16 |
| Calretinin (5%) | 5 (5.05) | 2 (2.02) | 92 (92.93) | 0.553 | 0.70 |
| CD34 (20%) | 10 (10.10) | 3 (3.03) | 86 (86.87) | 0.250 | 0.12 |
| CD56 (5%) | 34 (34.34) | 44 (44.44) | 21 (21.21) | 0.730 | 0.03* |
| CD68 (30%) | 15 (15.15) | 9 (9.09) | 75 (75.76) | −0.061 | 0.82 |
| CDX2 (50%) | 7 (7.07) | 2 (2.02) | 90 (90.91) | 0.169 | 0.52 |
| C-MET (25%) | 16 (16.16) | 6 (6.06) | 77 (77.78) | 0.034 | 0.56 |
| CgA (10%) | 20 (20.20) | 41 (41.41) | 38 (38.38) | 0.719 | 0.04* |
| CK (10%) | 6 (6.06) | 47 (47.47) | 46 (46.46) | −0.140 | 0.59 |
| CK20 (10%) | 11 (11.11) | 3 (3.03) | 85 (85.86) | −0.408 | 0.10 |
| CK7 (10%) | 26 (26.26) | 4 (4.04) | 69 (69.70) | −0.059 | 0.82 |
| CK8/18 (10%) | 27 (27.27) | 50 (50.51) | 22 (22.22) | 0.078 | 0.77 |
| Desmin (1%) | 13 (13.13) | 7 (7.07) | 79 (79.80) | 0.388 | 0.52 |
| E-cadherin (25%) | 3 (3.03) | 1 (1.01) | 95 (95.96) | 0.162 | 0.23 |
| ER (25%) | 12 (12.12) | 0.000 | 87 (87.88) | 0.316 | 0.20 |
| GATA3 (50%) | 14 (14.14) | 0.000 | 85 (85.86) | −0.343 | 0.18 |
| GATA6 (10%) | 51 (55.56) | 23 (23.23) | 25 (25.25) | 0.623 | 0.046* |
| GPA33 (1%) | 16 (16.16) | 0.000 | 83 (83.84) | 0.236 | 0.51 |
| HER2 (50%) | 12 (12.12) | 6 (6.06) | 80 (80.81) | 0.178 | 0.86 |
| HNF4α (1%) | 8 (8.08) | 0.000 | 91 (91.92) | 0.557 | 0.22 |
| Ki-67 (25%) | 15 (15.15) | 84 (84.85) | 0.000 | 0.119 | 0.67 |
| LCA (10%) | 6 (6.06) | 0.000 | 93 (93.94) | −0.086 | 0.74 |
| MTAP (50%) | 4 (4.04) | 0.000 | 95 (95.96) | 0.164 | 0.33 |
| MUC4 (5%) | 2 (2.02) | 0.000 | 97 (97.98) | 0.569 | 0.78 |
| Napsin A (25%) | 47 (47.47) | 52 (52.53) | 0.000 | 0.307 | 0.11 |
| P40 (10%) | 18 (18.18) | 0.000 | 81 (81.82) | 0.704 | 0.07 |
| P53 (50%) | 10 (10.10) | 66 (66.67) | 23 (23.23) | 0.278 | 0.59 |
| Pou2F3 (1%) | 5 (5.05) | 0.000 | 94 (94.95) | −0.030 | 0.91 |
| PD-L1 (1%) | 28 (28.28) | 37 (37.37) | 34 (34.34) | −0.064 | 0.81 |
| PR (5%) | 11 (11.11) | 1 (1.01) | 87 (87.88) | 0.318 | 0.23 |
| SALL4 (25%) | 51 (51.52) | 13 (13.13) | 35 (35.35) | 0.259 | 0.37 |
| SMARCA4 (25%) | 45 (45.45) | 54 (54.55) | 0.000 | 0.811 | 0.01* |
| Villin (10%) | 9 (9.09) | 0.000 | 90 (90.91) | 0.082 | 0.16 |
| WT-1 (1%) | 17 (17.17) | 0.000 | 82 (82.83) | −0.130 | 0.61 |
| ZEB1 (10%) | 5 (5.05) | 0.000 | 94 (94.95) | 0.454 | 0.059 |
| β-catenin (50%) | 36 (36.36) | 0.000 | 63 (63.64) | 0.426 | 0.09 |
For molecular expression, the percentage in parentheses represents the threshold for positive and negative expressions. *, P<0.05. CTC, circulating tumor cell; TTF-1, thyroid transcription factor-1; CK, cytokeratin; C-MET, cellular-mesenchymal to epithelial transition factor; LCA, leucocyte common antigen; MTAP, methylthioadenosine phosphorylase; ER, estrogen receptor; PD-L1, programmed cell death ligand 1; PR, progesterone receptor; SALL4, spalt-like transcription factor 4; SMARCA4, SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin; WT-1, Wilms tumor 1; ZEB1, zinc finger E-box binding homeobox 1.